{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005383","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.568484+00:00","generated_at":"2026-05-17T14:09:10.492549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aptose Q2 net loss $7.0M; cash $1.3M; CSRC okays TUS dose escalation to 160 mg","bullets":["Net loss $7.0M ($2.76 per share) for Q2 2025, vs. $7.3M in Q2 2024; loss per share improved on higher share count.","Cash and equivalents $1.3M as of June 30, 2025; company says cash insufficient to fund operations, relying on Hanmi loan of up to $8.5M.","Safety Review Committee approved dose escalation of tuspetinib to 160 mg in TUS+VEN+AZA TUSCANY trial; 120 mg cohort all patients remain on study.","All 10 enrolled subjects in TUSCANY triplet remain on treatment; CRs achieved at 40 mg and 80 mg doses across diverse AML mutations.","Selected EY as new auditor; annual meeting reconvened for August 22, 2025 to vote on appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005383","json":"https://secwatch.observer/filing/0001171843-25-005383.json","markdown":"https://secwatch.observer/filing/0001171843-25-005383.md","text":"https://secwatch.observer/filing/0001171843-25-005383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325005383/0001171843-25-005383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325005383/f8k_081325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:09:10.492549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}